Michelle I Silver, Scm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4349643/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Preventive Medicine, 2022, 154, 106871.	3.4	3
2	Rates of New Human Papillomavirus Detection and Loss of Detection in Middle-aged Women by Recent and Past Sexual Behavior. Journal of Infectious Diseases, 2021, 223, 1423-1432.	4.0	22
3	De-implementation of cervical cancer screening before age 21. Preventive Medicine, 2021, 153, 106815.	3.4	1
4	Exacerbating disparities?: Cervical cancer screening and HPV vaccination. Preventive Medicine, 2020, 130, 105902.	3.4	16
5	Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®. Breast Cancer Research and Treatment, 2019, 173, 719-726.	2.5	5
6	Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years. Cancer Prevention Research, 2018, 11, 165-170.	1.5	26
7	A prospective study of risk-based colposcopy demonstrates improved detection of cervicalÂprecancers. American Journal of Obstetrics and Gynecology, 2018, 218, 604.e1-604.e8.	1.3	23
8	Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30–65Âyears. Cancer Causes and Control, 2018, 29, 43-50.	1.8	20
9	Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause, 2018, 25, 1321-1330.	2.0	63
10	Risk of Cervical Intraepithelial Neoplasia 2 or Worse by Cytology, Human Papillomavirus 16/18, and Colposcopy Impression. Obstetrics and Gynecology, 2018, 132, 725-735.	2.4	25
11	Trends in cervical cancer incidence in younger US women from 2000 to 2013. Gynecologic Oncology, 2017, 144, 391-395.	1.4	10
12	The population impact of human papillomavirus/cytology cervical cotesting at 3â€year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. Cancer, 2016, 122, 3682-3686.	4.1	15
13	Comparison of Hybribio GenoArray and Roche Human Papillomavirus (HPV) Linear Array for HPV Genotyping in Anal Swab Samples. Journal of Clinical Microbiology, 2015, 53, 550-556.	3.9	14
14	Patient Concerns About Human Papillomavirus Testing and 5-Year Intervals in Routine Cervical Cancer Screening. Obstetrics and Gynecology, 2015, 125, 317-329.	2.4	45
15	Cervical Cancer Screening in Older Women: New Evidence and Knowledge Gaps. PLoS Medicine, 2014, 11, e1001586.	8.4	9
16	Shedding of Epstein-Barr Virus and Cytomegalovirus from the Genital Tract of Women in a Periurban Community in Andhra Pradesh, India. Journal of Clinical Microbiology, 2011, 49, 2435-2439.	3.9	31